Based in ICON’s Clinical Pharmacology Unit in San Antonio, US, Elahi will lead ICON’s early phase glucose clamping programs globally, providing expert, scientific consultation to sponsors who are developing therapeutic agents to treat endocrine/metabolic disease.Elahi is a clinical physiologist with over 30 years of research experience, predominantly focused on translational investigations of the regulation of glucose homeostasis in states of glucose tolerance and intolerance.
